RecruitingPhase 1NCT04147078

Personalized DC Vaccine for Postoperative Cancer

Adjuvant Treatment in Cancer Patients with Neoantigen-primed DC Vaccine : a Single-arm, Open-label, Prospective Clinical Trial

Sponsor

Sichuan University

Enrollment

80 participants

Start Date

Jun 1, 2019

Study Type

INTERVENTIONAL

Conditions

Gastric Cancer Hepatocellular Carcinoma

Summary

The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and to explore the biomarkers related to efficacy and adverse event.

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Inclusion Criteria4

Participants with a first diagnosis of gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, colorectal cancer who have undergone a curative resection or ablation
Anticipated life time \> 3month
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
Adequate organ functions

Exclusion Criteria6

Any evidence of tumor metastasis or co-existing malignant disease
Tumor emergency
Abnormal coagulation condition
Contagious diseases, such as hepatitis B virus, hepatitis C virus, human immunodefficiency virus, tuberculosis infection
Concomitant tumors
Immunological co-morbidities